RE245

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

RE245, or RE-245, is a non-hallucinogenic psychoplastogen which is under development for the treatment of psychiatric disorders. It is taken orally. The drug acts as a serotonin receptor modulator, including of the serotonin 5-HT 2A receptor, and is said to have psychoplastogenic effects. It is being developed by Reunion Neuroscience. As of August 2025, RE245 is in the preclinical research stage of development. An Investigational New Drug (IND) application to allow for phase 1 clinical trials is planned to be submitted in 2026, with these studies expected to start in 2027. The chemical structure of RE245 does not yet appear to have been disclosed.

RE245, or RE-245, is a non-hallucinogenic psychoplastogen which is under development for the treatment of psychiatric disorders. It is taken orally. The drug acts as a serotonin receptor modulator, including of the serotonin 5-HT 2A receptor, and is said to have psychoplastogenic effects. It is being developed by Reunion Neuroscience. As of August 2025, RE245 is in the preclinical research stage of development. An Investigational New Drug (IND) application to allow for phase 1 clinical trials is planned to be submitted in 2026, with these studies expected to start in 2027. The chemical structure of RE245 does not yet appear to have been disclosed.

See also

Non-hallucinogenic 5-HT 2A receptor agonist List of investigational hallucinogens and entactogens Luvesilocin (RE104; FT-104; 4-GO-DiPT)

References

Text derived from https://en.wikipedia.org/w/index.php?oldid=1372045749 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

5 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.